Intuitive Surgical, Inc. (ISRG)
NASDAQ · Healthcare · Medical - Instruments & Supplies
Profile
Intuitive Surgical, Inc.
- Exchange
- NASDAQ
- Ticker
- ISRG
- Sector
- Healthcare
- Industry
- Medical - Instruments & Supplies
- Country
- US
Intuitive Surgical, Inc. is a leading medical technology firm dedicated to advancing patient care by developing, producing, and commercializing sophisticated tools. These innovations empower medical professionals to deliver superior, accessible, and less-invasive treatment options to patients both within the United States and across international markets. Its flagship offering, the da Vinci Surgical System, facilitates intricate operations through a minimally disruptive approach. Expanding beyond surgical applications, the company also provides the Ion endoluminal system, designed for diagnostic interventions like minimally invasive lung biopsies. Complementing its primary systems, Intuitive Surgical supplies a comprehensive array of instruments, including stapling tools, energy devices, and essential core components. Furthermore, it offers structured training programs to ensure proficient use of its technology, alongside extensive customer support services encompassing installation, repairs, and ongoing maintenance. The firm also integrates digital capabilities to deliver unified, connected solutions that optimize hospital performance through actionable insights. Established in 1995, Intuitive Surgical maintains its corporate headquarters in Sunnyvale, California.
Key facts
Intuitive Surgical, Inc.: key facts
- Intuitive Surgical, Inc. (NASDAQ: ISRG) is a Medical - Instruments & Supplies company in the Healthcare sector.
- In fiscal 2025, Intuitive Surgical, Inc. reported revenue of $10.1B and net income of $2.9B.
- Revenue grew 15.2% a year over the last 4 fiscal years.
- Free cash flow was positive in 5 of the last 5 fiscal years.
- Net income was positive in 5 of the last 5 fiscal years.
- Over the last twelve months, revenue was $11.6B and net income was $3.0B.
MonkScore
Intuitive Surgical, Inc.'s MonkScore
MonkScore
MonkScore range: 90–100
as of October 2026
Sector rank: 23 of 628 in Healthcare
How this score is madeDisclaimer
Pillar ranges
- Growth90–100
- Profitability80–90
- Quality90–100
- Market Conviction90–100
- Safety60–70
The MonkScore runs from 0 to 100. Each range is one of ten 10-point groups, from 0–10 to 90–100.
Each pillar's range uses the same ten groups. The exact score and the pillar scores are in the MonkStreet app.
Fundamentals
Figures from the statements
Intuitive Surgical, Inc.'s annual figures and the last twelve months, in USD. Last report: 30 September 2026.
| Figure | Last 12 months | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Revenue | $11.6B | $10.1B | $8.4B | $7.1B | $6.2B | $5.7B |
| Gross profit | $7.8B | $6.6B | $5.6B | $4.7B | $4.2B | $4.0B |
| Operating income | $3.3B | $2.9B | $2.3B | $1.8B | $1.6B | $1.8B |
| Net income | $3.0B | $2.9B | $2.3B | $1.8B | $1.3B | $1.7B |
| Operating cash flow | $4.1B | $3.0B | $2.4B | $1.8B | $1.5B | $2.1B |
| Capital expenditure | -$491.5M | -$539.8M | -$1.1B | -$1.1B | -$532.4M | -$353.5M |
| Free cash flow | $3.6B | $2.5B | $1.3B | $749.6M | $958.4M | $1.7B |
| Total debt | $0.0 | $302.8M | $146.0M | $0.0 | $0.0 | $87.0M |
| Cash | $3.0B | $3.4B | $2.0B | $2.8B | $1.6B | $1.3B |
Revenue growth a year
- 1-year
- 20.5%
- 3-year
- 17.4%
- 4-year
- 15.2%
Compound growth between fiscal years.
Peers
Similar companies
- West Pharmaceutical Services, Inc.NYSE:WSTMonkScore range: 90–100
- ResMed Inc.ASX:RMDMonkScore range: 90–100
- ResMed Inc.NYSE:RMDMonkScore range: 90–100
- Sanara MedTech Inc.NASDAQ:SMTIMonkScore range: 80–90
- AtriCure, Inc.NASDAQ:ATRCMonkScore range: 80–90
- LeMaitre Vascular, Inc.NASDAQ:LMATMonkScore range: 70–80
- Merit Medical Systems, Inc.NASDAQ:MMSIMonkScore range: 60–70
- Avantor, Inc.NYSE:AVTRMonkScore range: 60–70
Score my top stocks · 14-day free trial · card required · not charged during the trial · cancel in one click
MonkStreet provides research, not investment advice.
Page built on 31 October 2026.